Effects of the DASH-JUMP dietary intervention in Japanese participants with high-normal blood pressure and stage 1 hypertension: an open-label single-arm trial

被引:25
|
作者
Kawamura, Atsuko [1 ,2 ]
Kajiya, Katsuko [1 ]
Kishi, Hiroko [1 ]
Inagaki, Junko [2 ]
Mitarai, Makoto [3 ]
Oda, Hiroshi [3 ]
Umemoto, Seiji [4 ]
Kobayashi, Sei [1 ]
机构
[1] Yamaguchi Univ, Grad Sch Med, Dept Mol Physiol & Med Bioregulat, 1-1-1 Minami Kogushi, Ube, Yamaguchi 7558505, Japan
[2] Yamaguchi Univ, Fac Hlth Sci, Grad Sch Med, Ube, Yamaguchi, Japan
[3] Maruha Nichiro Corp, Cent Res Inst, Tsukuba, Ibaraki, Japan
[4] Yamaguchi Univ, Ctr Clin Res, Ube, Yamaguchi, Japan
关键词
blood pressure; Dietary Approaches to Stop Hypertension diet; Japanese; lifestyle-related disease; SALT INTAKE; CARDIOVASCULAR-DISEASE; POTASSIUM INTAKE; CLINICAL-TRIAL; RISK-FACTORS; SODIUM; INFLAMMATION; PREVENTION; GUIDELINES; MANAGEMENT;
D O I
10.1038/hr.2016.76
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
The Dietary Approaches to Stop Hypertension (DASH) diet is recommended by the American Heart Association to lower blood pressure (BP); however, its effects in Japanese participants have not been rigorously studied. We assessed the effects of the DASH-Japan Ube Modified diet Program (DASH-JUMP), a modified DASH diet, on cardiometabolic and inflammatory biomarkers in Japanese participants with untreated high-normal BP or stage 1 hypertension. Fifty-eight participants (30 men and 28 women; mean age 54.1 +/- 8.1 years) with untreated high-normal BP or stage 1 hypertension followed the DASH-JUMP (salt 8.0 g per day) for 2 months. After the intervention period, they resumed their usual diets for 4 months. The DASH-JUMP significantly decreased the participants' body mass index values (24.6 +/- 3.5 kg m(-2) at baseline -> 23.2 +/- 3.3 kg m(-2) at 2 months, P=0.000), BP (153 +/- 14/91 +/- 11 mm Hg at baseline -> 130 +/- 16/80 +/- 9 mm Hg at 2 months, P=0.000 and 139 +/- 16/85 +/- 10 mm Hg at 6 months, P=0.000), fasting serum glucose level (100 +/- 26 mg dl(-1). 94 +/- 15 mg dl(-1) at 2 months, P=0.003) and fasting insulin level (6.9 +/- 5.9 mu IU ml(-1) -> 4.4 +/- 2.7 +/- mu IU ml(-1) at 2 months, P=0.000). The mean compliance of the participants for the DASH-JUMP diet was 88.5%. The DASH-JUMP diet reduced cardiovascular risk factors and may be an effective nutritional strategy for preventing cardiovascular events.
引用
收藏
页码:777 / 785
页数:9
相关论文
共 4 条
  • [1] Effects of the DASH-JUMP dietary intervention in Japanese participants with high-normal blood pressure and stage 1 hypertension: an open-label single-arm trial
    Atsuko Kawamura
    Katsuko Kajiya
    Hiroko Kishi
    Junko Inagaki
    Makoto Mitarai
    Hiroshi Oda
    Seiji Umemoto
    Sei Kobayashi
    Hypertension Research, 2016, 39 : 777 - 785
  • [2] Effects of a Japanese Cuisine-Based Antihypertensive Diet and Fish Oil on Blood Pressure and Its Variability in Participants with Untreated Normal High Blood Pressure or Stage I Hypertension: A Feasibility Randomized Controlled Study
    Umemoto, Seiji
    Onaka, Uran
    Kawano, Reo
    Kawamura, Atsuko
    Motoi, Sayaka
    Honda, Naoki
    Kanazashi, Hiroki
    Mitarai, Makoto
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2022, 29 (02) : 152 - 173
  • [3] Design and rationale for a randomized, open-label, parallel clinical trial evaluating major adverse cardiovascular events (pharmacological treatment versus diet control) in patients with high-normal blood pressure: the PRINT-TAHA9 trial
    Attar, Armin
    Mirhosseini, Seyed Alireza
    Borazjani, Roham
    Sayadi, Mehrab
    Ahadi, Mahsa
    Zibaeenezhad, MohammadJavad
    Razeghian-Jahromi, Iman
    Parsa, Nader
    TRIALS, 2024, 25 (01)
  • [4] The effects of Olmesartan/amlodipine administered in the Morning or At Night on nocturnal blood pressure reduction in Chinese patients with mild-moderate essential hypertension (OMAN Trial): study protocol for a prospective, multicenter, randomized, open-label clinical trial {1}
    Xu, Mengzhuo
    Zhang, Xin
    Ye, Runyu
    Liu, Xueting
    Sun, Lirong
    Jia, Shanshan
    Zhang, Zhipeng
    Li, Xinran
    Wang, Ziqiong
    Liao, Hang
    Shi, Rufeng
    Liu, Kai
    Wang, Si
    Meng, Qingtao
    Chen, Xiaoping
    TRIALS, 2023, 24 (01)